Healthcare Sector
Market Tracker
15m Chart - Support and Resistance levels are based on the large dark pool & equity prints at the plotted levels. Displays strongest levels above and below the spot price.
Represents the strikes that had the highest premium of whale flow (on the ASK side) over the past 5 trading days.
Represents the strikes that had the highest premium of whale flow (on the BID side) over the past 5 trading days.
Represents the largest cumulative premium levels above and below the current spot price. The price in the pink bubble represents the spot price.
Total Open Interest of Calls & Puts across all strikes and expirations over the past 16 trading days.
| Expires | Type | Strike | OI | Change | Percent |
|---|---|---|---|---|---|
| 06/18/2026 | PUT | $42.50 | 4,876 | +3,738 | +328.47% |
| 12/18/2026 | CALL | $50.00 | 15,239 | +2,309 | +17.86% |
| 06/05/2026 | PUT | $42.00 | 1,133 | +1,020 | +902.65% |
| 09/18/2026 | CALL | $65.00 | 3,990 | +951 | +31.29% |
| 06/05/2026 | PUT | $42.50 | 1,035 | +762 | +279.12% |
| 05/29/2026 | PUT | $42.50 | 1,258 | +584 | +86.65% |
| 05/29/2026 | PUT | $50.00 | 1 | -60 | -98.36% |
| 06/18/2026 | PUT | $60.00 | 809 | -107 | -11.68% |
| 06/18/2026 | CALL | $50.00 | 31,144 | -311 | -0.99% |
| 05/22/2026 | PUT | $46.50 | 0 | -1,246 | -100.00% |
| 05/22/2026 | PUT | $47.00 | 1 | -1,354 | -99.93% |
| 06/18/2026 | PUT | $55.00 | 8,370 | -3,752 | -30.95% |
Contracts with largest changes in open interest from the previous trading day to the current/most recent.
| Name | Pct Held | Shares | Total |
|---|---|---|---|
| Harbor Capital Appreciation Fund | 0.18% | 3.11M | 481.53M |
| Washington Mutual Investors Fund | 0.09% | 1.51M | 234.45M |
| Vanguard U.S. Growth Fund | 0.07% | 1.27M | 196.47M |
| Loomis Sayles Growth Fund | 0.07% | 1.18M | 183.13M |
| Fidelity Blue Chip Growth Fund | 0.07% | 1.13M | 175.35M |
| Amana Mutual Funds Trust-Growth Fund | 0.06% | 1M | 155.09M |
| PGIM Jennison Growth Fd | 0.05% | 828.11k | 128.15M |
| Blackrock Equity Dividend Fund | 0.04% | 712k | 110.18M |
| New Perspective Fund Inc | 0.04% | 691.44k | 107M |
| Price (T.Rowe) International Stock Fund | 0.04% | 674k | 104.3M |
The Most Important Healthcare Stock You're Not Watching
05/22 05:15 pm
The Motley Fool
Read moreNovo Nordisk A/S: CHMP recommends EU approval of Wegovy® 7.2 mg in a single-dose pen, providing up to 20.7% mean weight loss (1)
05/22 01:30 pm
GlobeNewswire Inc.
Read moreFrom Zepbound to Foundayo: Lilly’s Latest Results Support Oral GLP-1 Outlook
05/21 10:43 am
Investing.com
Read moreBest Weight Loss Drug Stocks to Buy in 2026
05/20 11:15 pm
The Motley Fool
Read moreEli Lilly Stock: Next Stop $2,000?
05/18 06:30 pm
The Motley Fool
Read moreIs Kailera Therapeutics a Buy After Its Sizzling IPO?
05/16 10:30 am
The Motley Fool
Read more2 Ways to Play the Big Pharma Patent Cliff
05/15 10:18 am
Investing.com
Read moreHims & Hers Stock Drops After Earnings: Buying Opportunity or Warning Sign?
05/15 05:05 am
The Motley Fool
Read moreIs Hims and Hers Health Stock a Buy After Its Latest Dip?
05/14 12:30 pm
The Motley Fool
Read moreShould Eli Lilly Investors Worry About Its Newest Rival -- From Within?
05/14 05:05 am
The Motley Fool
Read moreIs Novo Nordisk's Rebound for Real--or Just a Head Fake?
05/13 01:15 pm
The Motley Fool
Read moreNovo Nordisk Highlights New Wegovy Pill Data
05/13 12:28 pm
Benzinga
Read moreEli Lilly Says Newly Approved Foundayo, Lower-Dose Zepbound Help Sustain Weight Loss
05/13 11:33 am
Benzinga
Read moreHims & Hers Stock Plunges After Q1 Miss: Is the GLP-1 Pivot Enough to Fuel a Recov
05/12 01:49 pm
Investing.com
Read moreNovo Nordisk Presents New Wegovy Data Showing Strong Weight Loss, Fat Reduction
05/12 01:22 pm
Benzinga
Read moreWhy Hims & Hers Health Stock Just Crashed
05/12 11:32 am
The Motley Fool
Read moreThe $59B Quiet Shift Reshaping How Patients Access Care
05/12 10:30 am
Benzinga
Read moreHims & Hers Earnings Preview: The Novo Nordisk Shift Puts GLP-1 Strategy in Focus
05/08 12:20 pm
Investing.com
Read moreCMS To Offer Wegovy To Eligible Medicare Patients At $50 Monthly Copay Starting July 2026
05/07 11:42 am
Benzinga
Read moreWegovy Pill Debut 'Fattens' Novo Nordisk's Profit Outlook
05/06 07:43 am
Benzinga
Read moreNovo Nordisk's adjusted operating profit reached DKK 32,858 million in Q1 2026
05/06 01:31 am
GlobeNewswire Inc.
Read moreHemophilia Clinical Trial Pipeline Gains Momentum: 50+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight
05/05 01:00 pm
GlobeNewswire Inc.
Read moreLilly’s Double-Beat Widens the GLP-1 Gap—And a New Pill Could Make It Permanent
05/01 02:45 pm
Investing.com
Read moreWhat's the Next Big Thing After GLP-1 Drugs? CRISPR Therapeutics May Have the Answer.
04/30 05:10 am
The Motley Fool
Read moreRetatrutide Crosses the Surgical Threshold, but the Real Race Has Just Started
04/29 11:00 am
GlobeNewswire Inc.
Read moreIs Eli Lilly Stock Undervalued at $870? 1 Top Wall Street Analyst Thinks So
04/28 06:15 pm
The Motley Fool
Read moreNovo Nordisk to present new data on Wegovy®, women with obesity and next-generation weight loss treatments at European Congress on Obesity
04/28 08:00 am
GlobeNewswire Inc.
Read moreIs This Deal a Game Changer for Novo Nordisk?
04/27 08:30 pm
The Motley Fool
Read moreForget Weight Loss Drugs: Here's An Even Better Reason to Invest in Eli Lilly
04/27 08:15 pm
The Motley Fool
Read moreFangzhou Publishes 2025 Annual Report, Advancing AI-Powered Chronic Care Strategy for 2026
04/27 02:52 am
GlobeNewswire Inc.
Read moreThis Obesity Stock Could More Than Double Over the Next 12 Months, According to Wall Street
04/26 10:02 am
The Motley Fool
Read moreIs This Tech Giant the Next Potential Winner in the GLP-1 Weight Loss Boom?
04/25 01:05 pm
The Motley Fool
Read moreWhy Eli Lilly Stock Flopped on Friday
04/24 06:30 pm
The Motley Fool
Read moreHims & Hers Positions Itself As Supply Anchor In Hormone Therapy Crunch
04/23 12:19 pm
Benzinga
Read moreKailera Therapeutics' Strong IPO Validates "NewCo" Strategy
04/23 12:08 pm
Benzinga
Read moreNovo Nordisk Eyes Approval For Potential First Oral GLP-1 Diabetes Pill In Young Patients
04/23 11:50 am
Benzinga
Read moreIs Novo Nordisk's 72% Crash a Generational Buying Opportunity or a Value Trap?
04/23 09:30 am
The Motley Fool
Read moreForget Ozempic: This High‑Flying Device Maker Can Thrive No Matter Which Weight Loss Drug Wins
04/23 05:30 am
The Motley Fool
Read moreA Monthly Weight Loss Shot? Why Pfizer Could Topple Lilly's and Novo's GLP-1 Duopoly
04/21 07:30 am
The Motley Fool
Read moreHere's Why Agios Pharmaceuticals Crashed 23% Today
04/20 12:19 pm
The Motley Fool
Read moreThis Drug Stock Has Crushed the S&P 500 Over the Last Decade
04/18 05:15 pm
The Motley Fool
Read moreKailera Therapeutics Debut Marks Largest Biotech IPO Since 2021 Amid Weight Loss Race
04/17 01:23 pm
Benzinga
Read moreNovo Nordisk Extends Lead As Eli Lilly New Obesity Pill Sees Modest Launch Uptake
04/17 12:04 pm
Benzinga
Read moreChina Diabetes Devices Market Forecast and Company Analysis Report 2026-2034 Featuring Roche, Abbott Laboratories, Novo Nordisk, BD, Medtronic, Eli Lilly, and Sanofi
04/17 12:00 pm
GlobeNewswire Inc.
Read moreIs Viking Therapeutics the Ultimate Millionaire-Maker Obesity Stock for 2026?
04/17 05:10 am
The Motley Fool
Read morePrediction: This 1 Thing Could Cement Eli Lilly's Leadership in the Billion-Dollar Weight Loss Drug Market
04/16 04:08 am
The Motley Fool
Read moreThe $1 Trillion Race: Why Eli Lilly Is Leaving Novo Nordisk in the Dust
04/15 01:26 pm
The Motley Fool
Read more